BACKGROUND: Non-AIDS-defining cancers (non-ADCs) have become the leading non-AIDS-related cause of death among people with HIV/AIDS. We aimed to quantify the excess risk of cancer-related deaths among Italian people with AIDS (PWA), as compared with people without AIDS (non-PWA). METHODS: A nationwide, population-based, retrospective cohort study was carried out among 5285 Italian PWA, aged 15-74 years, diagnosed between 2006 and 2011. Date of death and multiple-cause-of-death data were retrieved up to December 2011. Excess mortality, as compared with non-PWA, was estimated using sex- and age-standardized mortality ratios (SMRs) and the corresponding 95% confidence intervals (CIs). RESULTS: Among 1229 deceased PWA, 10.3% reported non-ADCs in the death certificate, including lung (3.1%), and liver (1.4%), cancers. A 7.3-fold (95% CI: 6.1 to 8.7) excess mortality was observed for all non-ADCs combined. Statistically significant SMRs emerged for specific non-ADCs, ie, anus (5 deaths, SMR = 227.6, 95% CI: 73.9 to 531.0), Hodgkin lymphoma (12 deaths, SMR = 122.0, 95% CI: 63.0 to 213.0), unspecified uterus (4 deaths, SMR = 52.5, 95% CI: 14.3 to 134.5), liver (17 deaths, SMR = 13.2, 95% CI: 7.7 to 21.1), skin melanoma (4 deaths, SMR = 10.9, 95% CI: 3.0 to 27.8), lung (38 deaths, SMR = 8.0, 95% CI: 5.7 to 11.0), head and neck (9 deaths, SMR = 7.8, 95% CI: 3.6 to 14.9), leukemia (5 deaths, SMR = 7.6, 95% CI: 2.4 to 17.7), and colon-rectum (10 deaths, SMR = 5.4, 95% CI: 2.6 to 10.0). SMRs for non-ADCs were particularly elevated among PWA infected through injecting drug use. CONCLUSION: This population-based study documented extremely elevated risks of death for non-ADCs among PWA. These findings stress the need of preventive interventions for both virus-related and non-virus-related cancers among HIV-infected individuals.
BACKGROUND:Non-AIDS-defining cancers (non-ADCs) have become the leading non-AIDS-related cause of death among people with HIV/AIDS. We aimed to quantify the excess risk of cancer-related deaths among Italian people with AIDS (PWA), as compared with people without AIDS (non-PWA). METHODS: A nationwide, population-based, retrospective cohort study was carried out among 5285 Italian PWA, aged 15-74 years, diagnosed between 2006 and 2011. Date of death and multiple-cause-of-death data were retrieved up to December 2011. Excess mortality, as compared with non-PWA, was estimated using sex- and age-standardized mortality ratios (SMRs) and the corresponding 95% confidence intervals (CIs). RESULTS: Among 1229 deceased PWA, 10.3% reported non-ADCs in the death certificate, including lung (3.1%), and liver (1.4%), cancers. A 7.3-fold (95% CI: 6.1 to 8.7) excess mortality was observed for all non-ADCs combined. Statistically significant SMRs emerged for specific non-ADCs, ie, anus (5 deaths, SMR = 227.6, 95% CI: 73.9 to 531.0), Hodgkin lymphoma (12 deaths, SMR = 122.0, 95% CI: 63.0 to 213.0), unspecified uterus (4 deaths, SMR = 52.5, 95% CI: 14.3 to 134.5), liver (17 deaths, SMR = 13.2, 95% CI: 7.7 to 21.1), skin melanoma (4 deaths, SMR = 10.9, 95% CI: 3.0 to 27.8), lung (38 deaths, SMR = 8.0, 95% CI: 5.7 to 11.0), head and neck (9 deaths, SMR = 7.8, 95% CI: 3.6 to 14.9), leukemia (5 deaths, SMR = 7.6, 95% CI: 2.4 to 17.7), and colon-rectum (10 deaths, SMR = 5.4, 95% CI: 2.6 to 10.0). SMRs for non-ADCs were particularly elevated among PWA infected through injecting drug use. CONCLUSION: This population-based study documented extremely elevated risks of death for non-ADCs among PWA. These findings stress the need of preventive interventions for both virus-related and non-virus-related cancers among HIV-infected individuals.
Authors: Mary Jo Trepka; Rehab Auf; Kristopher P Fennie; Diana M Sheehan; Lorene M Maddox; Theophile Niyonsenga Journal: Am J Prev Med Date: 2017-07-24 Impact factor: 5.043
Authors: David J Riedel; Kristen A Stafford; Aparna Vadlamani; Robert R Redfield Journal: AIDS Res Hum Retroviruses Date: 2016-12-13 Impact factor: 2.205
Authors: Mohamed Abdel-Mohsen; Leticia Kuri-Cervantes; Judith Grau-Exposito; Adam M Spivak; Racheal A Nell; Costin Tomescu; Surya Kumari Vadrevu; Leila B Giron; Carla Serra-Peinado; Meritxell Genescà; Josep Castellví; Guoxin Wu; Perla M Del Rio Estrada; Mauricio González-Navarro; Kenneth Lynn; Colin T King; Sai Vemula; Kara Cox; Yanmin Wan; Qingsheng Li; Karam Mounzer; Jay Kostman; Ian Frank; Mirko Paiardini; Daria Hazuda; Gustavo Reyes-Terán; Douglas Richman; Bonnie Howell; Pablo Tebas; Javier Martinez-Picado; Vicente Planelles; Maria J Buzon; Michael R Betts; Luis J Montaner Journal: Sci Transl Med Date: 2018-04-18 Impact factor: 17.956
Authors: Anna E Coghill; Xuesong Han; Gita Suneja; Chun Chieh Lin; Ahmedin Jemal; Meredith S Shiels Journal: Cancer Date: 2019-05-03 Impact factor: 6.860
Authors: Surya Kumari Vadrevu; Irena Trbojevic-Akmacic; Andrew V Kossenkov; Florent Colomb; Leila B Giron; Alitzel Anzurez; Kenneth Lynn; Karam Mounzer; Alan L Landay; Robert C Kaplan; Emmanouil Papasavvas; Luis J Montaner; Gordan Lauc; Mohamed Abdel-Mohsen Journal: J Leukoc Biol Date: 2018-04-06 Impact factor: 4.962
Authors: Surbhi Grover; Fidel Desir; Yuezhou Jing; Rohini K Bhatia; Daniel M Trifiletti; Samuel Swisher-McClure; Julie Kobie; Richard D Moore; Charles S Rabkin; Michael J Silverberg; Kate Salters; William Christopher Mathews; Michael John Gill; Jennifer E Thorne; Jessica Castilho; Mari M Kitahata; Amy Justice; Michael A Horberg; Chad J Achenbach; Angel M Mayor; Keri N Althoff Journal: J Acquir Immune Defic Syndr Date: 2018-12-01 Impact factor: 3.771
Authors: Krishna P Reddy; Chung Yin Kong; Emily P Hyle; Travis P Baggett; Mingshu Huang; Robert A Parker; A David Paltiel; Elena Losina; Milton C Weinstein; Kenneth A Freedberg; Rochelle P Walensky Journal: JAMA Intern Med Date: 2017-11-01 Impact factor: 44.409